(SWX:BSLN.SW),(Boerse Stuttgart – Freiverkehr:BSLN),(Boerse Berlin – Freiverkehr:BSLN),(Boerse Frankfurt – Freiverkehr:BSLN),(Boerse Muenchen – Freiverkehr:BSLN), Clinical portfolio strengthened through the in-licensing of phase 3-ready antibiotic ceftibuten-ledaborbactam Fosmanogepix second phase 3 study initiated; two phase 3 studies in invasive fungal infections progressing as planned Two new preclinical collaborations to develop novel antibacterial and antifungal drugs Cresemba continued strong […]

Basilea provides portfolio update and outlook GlobeNewswire January 08, 2026 Clinical portfolio strengthened through the in-licensing of phase 3-ready antibiotic ceftibuten-ledaborbactam Fosmanogepix second phase 3 study initiated; two phase 3 studies in invasive fungal infections progressing as planned Two new preclinical collaborations to develop novel antibacterial and antifungal drugs Cresemba continued strong double-digit in-market sales

(Paris:SW), Issy-les-Moulineaux, January 8, 2026 (7am)Sodexo (Euronext Paris FR 0000121220-OTC: SDXAY) Q1 organic revenue growth of +1.8% Fiscal 2026 guidance framework unchanged: Organic revenue growth between +1.5% and +2.5% Underlying operating profit margin to be slightly lower than Fiscal 2025 Q1 FISCAL 2026 REVENUES REVENUES(in million euros) Q1 FY26 Q1 FY25 ORGANICGROWTH EXTERNALGROWTH CURRENCYEFFECT TOTALGROWTH

(Euronext Amsterdam:PHARM),(NasdaqGM:PHARM),(Euronext Amsterdam:PHARM), Leiden, The Netherlands, January 8, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor Day on February 3, 2026, at 10:00 am EST (16:00 CET). Total 2025 revenues are estimated to

Sodexo Q1 Fiscal 2026 revenues in line with expectations GlobeNewswire January 08, 2026 Issy-les-Moulineaux, January 8, 2026 (7am)Sodexo (Euronext Paris FR 0000121220-OTC: SDXAY) Q1 organic revenue growth of +1.8% Fiscal 2026 guidance framework unchanged: Organic revenue growth between +1.5% and +2.5% Underlying operating profit margin to be slightly lower than Fiscal 2025 Q1 FISCAL 2026

Pharming Group reports preliminary 2025 revenues and announces Investor Day GlobeNewswire January 08, 2026 Leiden, The Netherlands, January 8, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor Day on February 3, 2026, at

LAS VEGAS, Jan. 08, 2026 (GLOBE NEWSWIRE) — CES 2026 has kicked off in Las Vegas, widely seen as the year when AI truly steps into the real world. Vbot made its CES debut with its SuperDog, which stood out for its no-remote-control operation, real-time environmental understanding, and proactive following capabilities. These features enabled direct

Vbot SuperDog Makes Its CES 2026 Debut, Signaling the Rise of Consumer Embodied AI GlobeNewswire January 08, 2026 LAS VEGAS, Jan. 08, 2026 (GLOBE NEWSWIRE) — CES 2026 has kicked off in Las Vegas, widely seen as the year when AI truly steps into the real world. Vbot made its CES debut with its SuperDog,

(NASDAQ:AUID), New global customer win underscores authID's growing leadership in workforce verification and the urgent need for deepfake-resistant identity proofing in hiring DENVER, Jan. 08, 2026 (GLOBE NEWSWIRE) — authID (Nasdaq: AUID), a leading provider of biometric identity verification and authentication solutions, today announced that one of the world's largest workforce solutions providers has selected

authID and TurboCheck Selected by Global Workforce Solutions Provider to Address the Surge of Employment Identity Fraud GlobeNewswire January 08, 2026 New global customer win underscores authID's growing leadership in workforce verification and the urgent need for deepfake-resistant identity proofing in hiring DENVER, Jan. 08, 2026 (GLOBE NEWSWIRE) — authID (Nasdaq: AUID), a leading provider